(VIANEWS) – Shares of NANOBIOTIX (CAC 40: NANO.PA) dropped by a staggering 11.52% to €4.65 at 14:05 EST on Tuesday, after two consecutive sessions in a row of gains. CAC 40 is falling 1.06% to €7,361.77, after two consecutive sessions in a row of gains. This seems, so far, an all-around down trend trading session today.
NANOBIOTIX’s last close was €5.25, 4.37% under its 52-week high of €5.49.
About NANOBIOTIX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-2.93.
Revenue Growth
Year-on-year quarterly revenue growth grew by 159.6%, now sitting on 4.78M for the twelve trailing months.
Moving Average
NANOBIOTIX’s value is way above its 50-day moving average of €3.16 and way higher than its 200-day moving average of €3.65.
More news about NANOBIOTIX (NANO.PA).
